TOP
BIBLIOGRAPHY - BIBLIOGRAFIJA


 
Dr. Hamza Mujagić
Massachusetts General Hospital and Harvard University, Boston, USA

Međunarodne knjige

1. Mujagić H, urednik. Imunologija Univerzitet u Tuzli, 2006. Knjiga je temeljna imunologija i u završnoj je fazi obrade. Sudjeluju autori iz Bosne, Hrvatske, Slovenije i USA.


Poglavlja u međunarodnim knjigama

1. Silobrčić V, Milas L, Mujagić H. Experimental lung metastases as a test in tumour immunology. Doll R, Vodopija I, eds. Host environmental interactions in the ethyology of cancer in man. WHO IARC, 1972: 411-417.

2. Curt GA, Allegra CJ, Fine RL, Mujagić H, Yeh GC, Chabner BA. Cancer Chemotherapy. Ulmann’s Encyclopedia of Chemistry. VCH Verlagsgesellschaft, 1986; A5: 1-28.

3. Supko GJ, Puchalski AT, Mujagic H, Zhu AX, Chabner BA. Clinical Pharmacology of Anticancer Drugs. Handin RI, Lux SE, Stossel TP, eds. Handin’s Textbook of Hematology. Lippincott Williams & Wilkins, 2002: 2095-2133.

4. Mujagic Hamza: Thalidomide and its analogs. Harrisons Textbook of Medicine, Harrisons Oncology. Lippincott Williams and Wilkins, 2006 (in print).

5. Mujagic Hamza: The Taxanes. Harrisons Textbook of Medicine, Harrisons Oncology. Lippincott, Williams and Wilkins, 2006 (in print).



Domaće knjige

1. Mujagić H. Praktikum iz Patološke fiziologije. Banjaluka: Univerzitet u Banjaluci, 1987.

2. Mujagić H. Odabrana poglavlja iz Patološke fiziologije. Banjaluka: Univerzitet u Banjaluci, 1988.

3. Nurkić M, Mujagić H. Imunološki riječnik. Tuzla: Univerzitet u Tuzli, 2001.


Naučne monografije

1. Mujagić H, Radovanović Z, Cuculić M, Vujanović N, Vujić A, Čobić P. SSID-a, Sindrom Stečene Imunodeficitarnosti, AIDS: Svjetlost- Sarajevo, 1988.

2. Mujagić Hamza, Mujagić Zlata: Agresivnost tumorske bolesti.

Izdavačko poduzeće Hamidović, Tuzla, 2003.


Znanstveni radovi u međunarodnim časopisima

Dr. Hamza Mujagić1. Milas L, Mujagić H. Protection by Corynebacterium parvum against tumor cells injected intravenously. Europ J Clin Biol Res 1972; 17: 498-500.

2. Milas L, Mujagić H. The effect of splenectomy on fibrosarcoma metastases in lungs of mice. Int J Cancer 1973; 11: 186-190.

3. Mujagić H, Krušić J, Dešković M, Malenica B. Immunological reactivity to non-specific antigens in cervical carcinoma patients. Period Biol 1976; 78: 151-153.

4. Mujagić H, Nola P, Malenica B, Maričić Ž, Allegretti N. Immunological reactivity in colorectal carcinoma patients with special reference to the new classification of carcinomas of colon and rectum. Period Biol 1976; 78: 153-155.

5. Mujagić H, Mažuran R, Malenica B, Silobrčić V. Clinical detection of cellular immunity to melanoma-specific antigens in men by the monocyte spreading inhibition test: correlation between in vivo and in vitro immunological test parameters. Period Biol 1976; 78: 156-157.

6. Mažuran R, Mujagić H, Malenica B, Silobrčić V. In vitro detection of cellular immunity to melanoma antigens in men by the monocyte spreading inhibition test. Int J Cancer 1976; 17: 14-20.

7. Rogan J, Mujagić H, Malenica B. Lymphocyte cytotoxicity to malignant melanoma and cervical carcinoma cells. Period Biol 1976; 78: 155-156.

8. Malenica B, Mujagić H, Kolarić K, Radetić M, Maričić Ž, Roguljić A, Rogan J, Vukas D. BCG immunotherapy in metatsatic malignant melanoma. Period Biol 1976; 78: 158-159.

9. Mujagić H.The chemotherapy of gastric carcinoma.The Medical Herald 1978;14:71-76.

10.Mujagić H, Kolarić K, Malenica B, Nola P. BCG immunotherapy in previously treated malignant melanoma patients. Biomedicine, 1979; 30: 95-102.

11.Mujagić H. Immunotherapy with BCG: an attempt at standardization of methods based on our experience and results. Period Biol 1980; 82(2): 195-205.

12.Mujagić H, Dešković M, Malenica B, Bistrović M, Krušić J. The significance of tuberculin immunity testing in cancer patients (invited article). Cell Molec Biol 1980; 26: (2):111-123.

13.Mujagić H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of Vincristine on Cell Survival, Cell Cycle Progression, and Mitotic Accumulation in asynchronously growing Sarcoma 180 Cells. Cancer Res 1983; 43: 3591-3597.

14.Mujagić H, Conger BM, Smith CE, Occipinti SJ, Shuette WH, Schackney SE. Schedule dependence of Vincristine lethality in sarcoma 180 cells following partial synchronisation with Hydroxiurea. Cancer Res 1983; 43: 3598-3603.

15.Malenica B, Mujagić H, Popović S, Eljuga D, Allegretti N, Rogan-Grgas J. Immunocompetence in patients with malignant melanoma. Period Biol 1983; 16: 351-353.

16.Shuette WH, Chen SS, Occipinti SJ, Mujagić H, Shackney SE. Automated radioautographyc grain counting: correction for grain overlap. Cell Tissue Kinet 1983; 16: 221-227.

17.Mujagić H, Shackney CE, Smith CE, Chen SS. Quantitative changes in surface immunoglobulin expression in WEHI-231 lymphoma cells in relation to their proliferative rate. Oncology, 1986; 43: 237-242.

18.Krnjajić N, Jevrić A, Krnjajić Z, Filipović I, Mujagić, H. Comparison of PGE and PGE2 levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Prog Clin Res 1987; 242: 119-122.

19.Mujagić H, Krnjajić N, Jevrić A. The levels and relations of prostaglandins in pregnant and non-pregnant tumor-bearing mice. J Cancer Res Clin Oncol 1989; 115: 383-387.

20.Mujagić H. Aggressive chemotherapy and sensitivity persistance to anticancer drugs.

Ann Paul Debre Hosp 1990; 41: 7-15.

21.Mujagić H, Mujagić Z. Detection of pleyotropic drug resistance by the rapid immunofluorescence assay of drug effects on cell skeleton. Oncology 1991; 48(3): 202-209.

22.Mujagić H, Blitvić A, Omeragić F. I can see you but you can not see me. Updates 1999; 1(3): 4 -11.

23. Mujagic H, Chabner BA. Thalidomide. MD Vista J Med 2001; 4: 1-7.

24.Mujagić H, Chabner BA, Mujagić Z. The mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002; 43(3): 274-285.

25.Mujagić Z, Mujagić H. Circulating levels of prolactin as an indicator of effectiveness of therapy in breast cancer patients. Int J Cancer 2002; Suppl 13: 216.

26.Mujagić Z, Mujagić H. Prolactin–new tumor marker for breast cancer? Turk J Biochem 2003; 28 (3): 120-121.

27.Mujagic Z, Mujagic H. Importance of serum prolactin determinations in metastatic breast cancer patients. Croat Med J. 2004; 45(2): 176-180.

28.Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Turk J Biochem. 2004; 29 (4): 277-281.

29.Pranjic N, Mujagic H. Gasoline sniffing and lead toxicity in workers at gasoline stations. J Occup Env Med. 1998; 40(11): 1024-1029.


Znanstveni radovi u zbornicima međunarodnih kongresa i simpozija

1.Mujagić H, Kolarić K. The value of immunological skin tests in Oncology. Book of abstracts of the Sec Int Cong Bulgarian Oncol, Varna, 1970. p.104.

2.Mažuran R, Mujagić H, Silobrčić V. Cellular immunity in vitro to melanoma-specific antigens in men detected by the macrophage spreading inhibition test. Book of abstracts of the 3th Europ Immunol Meeting, Amsterdam, 1975. p. 125.

3.Mujagić H, Milas L, Allegretti N, Nola P, Malenica B, Maričić Ž. Immunological reactivity in colorectal carcinoma patients with special reference to the new T-S classification of carcinomas on the colon and rectum. Book of abstracts of the Tenth Int Congr Gastroenter, Budapest, 1976. p. 412.

4.Mujagić H, Dešković M, Malenica B. Tuberculin immunity in cancer patients; clinical and prognostic significance. Bok of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 126.

5.Mujagić H, Kolarić K, Nola P. Immunological status in malignant melanoma patients. Book of abstracts of the 12th Int Cancer Congr, Buenos Aires, 1978. p. 188.

6.Mujagić H. Clinical immunological status in malignant melanoma patients. Book of abstracts of the 6th Europ Immunol Meeting, Paris, 1980. p. 188.

7.Mujagić H, Smith CE, Shuette WH, Shackney SE. The cell tubulin content frequency histogram obtained by flow cytometry in sarcoma 180 cells in vitro. Proc Am Assoc Cancer Res, Denver, 1982. p. 105.

8.Chen SS, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Multiparameter radiographic image abalysis studies in human lymphomas. Proc Am Assoc Clin Oncol, Denver, 1982. p. 107.

9.Conger B, Occipinti SJ, Mujagić H, Smith CE, Shuette WH, Shackney SE. Studies on lethal and sublethal effects of Vincristine on sarcoma 180 cells in vitro. Proc Am Soc Cell Kin, Houston, 1982. p. 32.

10.Radičević N, Mujagić H. The effect of methylnitrosourea (MNU) on the growth of transplanted methylcholanthrene-induced fibrosarcoma in Balb/c mice. Book of abstracts of the Second World Congress of Pharmacology, Tokyo, 1982. p. 103.

11.Radičević N, Mujagić H. The relationship of macrophage spreading inhibition (MSI) with tumor growth and non-specific immunotherapy. Book of abstracts of the 2th World Cong Pharmacol, Tokyo, 1982: Abs.10.5.56.

12.Mujagić H. Tumor-directed immune reactivity in malignant melanoma patients. Book of abstracts of the 2th World Congr Pharmacol, Tokyo, 1982: Abs.10.5.51.

13.Mujagić H, Smith CE, Occipinti S, Shuette WH, Shackney SE. The quantitative changes in immunoglobulin contents on the surface of WEHI-231 lymphoma cells in relation to their proliferative rate. Proc Am Assoc Cancer Res, Atlanta, 1983. p. 32.

14.Curt GA, Bailey BD, Mujagić H, Chabner BA. Pleiotropic drug resistance in MCF-7 human breast carcinoma cell line. Proc Am Assoc Cancer Res, Houston, 1984. p. 104.

15.Petronijević S, Krnjajić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic Balb/c mice with transplanted methylcholanthrene fibrosarcoma. Joint Meeting Jugosl Finish Pharm, Dubrovnik, 1986. p. 66.

16.Krnjajić N, Petronijević S, Jevrić A, Krnjajić Z, Mujagić H. PGFalfa and PGF2alfa levels in pregnant syngeneic Balb/c mice with transplanted fibrosarcoma. Book of abstracts of the 6th Conf Prostagl Rel Comp, Florence, 1986. p. 206.

17.Krnjaić N, Jevrić A, Mujagić H, Krnjaić Z. The relationship between the levels of PGE1 and PGE2 and macrophage spreading inhibition in tumor bearing mice. 3th Int Symp Prostagland, Bad Ischly, 1986. p. 17.

18.Mujagić Z, Mujagić H. Diagnostic and Prognostic Usefulness of Prolactin (PRL) in Breast Cancer (BC). Proc. ASCO, San Francisco, 2001. p. 20 (43b).

19.Mujagić Z, Mujagić H. Prognostic significance of circulating levels of prolactin (PRL) in metastatic breast cancer (MBC). Proc ASCO, Chicago, 2003. p. 22(49).

20.Mujagic Z, Cicko E, Mujagic H. Circulating levels of prolactin before, during and after surgery in patients under total intravenous and general balanced anesthesia. Proceedings of IMMPC-2, Antalya, Turkey 2004.

21.Mujagic Z, Mujagic H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Proceedings of the 4th European Conference: «Perspectives in breast cancer», Madrid Spain 2004. p. 22.


Znanstveni radovi u domaćim časopisima

1.Mujagić H, Malenica B, Nola P, Maričić Ž, Kolarić K. BCG immunotherapy applied after surgery in malignant melanoma patients. The Med Rev, Galenika 1976; 16: 42-48.

2.Mujagić H, Roth A, Smudj K, Malenica B, Juzbašić S. Immunotherapy and chemotherapy in the treatment of advanced osteosarcoma–A case report. Iugosl Orthopaed Acta 1977; 2: 209-213.

3.Mujagić H. The possibilities of immunotherapy of malignant tumors in men. Med Arch 1978; 32: 43-49.

4.Mujagić H. The monitoring of lymphocyte blast specific and non-specific transformation in malignant melanoma patients and the possibilities of clinical utilisation of results. Radiol Jugosl 1978; 12: 794-804.

5.Krnjajić N, Jevrić A, Petronijević S, Krnjajić Z, Mujagić H. PGE2 levels in pregnant syngeneic BaLb/c mice with transplanted methylcholanthrene fibrosarcoma. Iugoslav Physiol Pharmacol Acta, 1985; 21 (3): 191-192.

6.Pertonijević S, Krnjaić N, Jevrić A, Mujagić H. PGF2 alfa levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Iugoslav Physiol Pharmacol Acta 1985; 21(suppl.3)p. 66.

7.Mujagić H. Morphological changes in cell skeleton caused by anticancer drugs. Inform karcinog 1990; 7: 9-23.

8.Pjanić A, Unčanin D, Sarajlić O, Abaspahić E, Mujagić H. Detection of cellular immunity in gastrointestinal carcinoma patients by the leucocyte adherence inhibition assay. Scripta Medica, 1991; 22: 10-16.

9.Šabanović Z, Mujagić H, Bazrdjanović M. Quality of medical records as a basis for DRG classification in the health care system in Bosnia and Hercegovina. Med Arch 1999; 53 (suppl 3): 61-64.

10.Ljuca Dž, Fatušić Z, Mujagić H, Ljuca F, Alispahić N. Precarcinoma and early carcinomatous lesions in the uterine cervix and the use of oral contraceptives. Med Arch 2000; 54 (2): 71-73.

11.Pranjić N, Mujagić H, Nurkić M, Karamehić J, Pavlović S. Assessment of health effects in workers at gasoline stations. Bosnian Journal of Basic Medical Sciences 2002, 2 (1-2): 35-45.

12.Pranjić N, Mujagić H, Pavlović S. Inhalation of gasoline and damage to health in workers at gasoline stations. Med Arch 2003; 57 (1): 17-20.

13.Mujagić H, Prnjavorac B, Mujagić Z, Festa G. Alcohol in alcoholic liver disease is a causative factor for development of allergic skin manifestations. Med Arch 2003; 57 (5-6): 273-278.

14.Mujagić Z, Mujagić H. Diagnostic usefulness of serum carcinoembryonic antigen determinations in breast cancer patients. Bosnian Journal of Basic Medical Sciences 2003; 3 (2): 30-34.

15.Mujagić Z, Mujagić H, Prnjavorac B. Circulating levels of prolactin in breast cancer patients. Med Arch 2005;59 (1):33-35.

16.Mujagić Z, Mujagić H, Prnjavorac B. The relationship between carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004;58 (1): 23-26.

17.Mujagić Z, Mujagić H, Prnjavorac B. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients. Med Arch 2004; 58 (1): 23-26



Znanstveni radovi u zbornicima domaćih kongresa i simpozija

1.Mujagić H, Milas L. The effect of Corynebacterium parvum on the growth of experimental metastases of fibrosarcoma in the lungs of C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p. 68.

2. Milas L, Mujagić H. The growth of experimental metastases of fibrosarcoma in the lungs of splenectomised C57BL mice. Proc Jugosl Immunol Soc, Beograd 1971. p. 67.

3.Mujagić H, Milas L, Malenica B, Jurčić D, Krušić J. Immunological reactivity in patients with rectal carcinoma. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 77.

4.Malenica B, Mujagić H, Radetić M, Maričić Ž, Roguljić A, Vukas D. BCG immunostimulation in malignant metastatic melanoma patients. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 30.

5.Mujagić H, Krušić J, Dešković M, Malenica B. Imunološka reaktivnost nespecifične antigene u bolesnica s karcinomom cerviksa. Book of abstracts of the Sixth Congr Jugosl Oncol,Sarajevo, 1975: 35.

6.Mujagić H, Mažuran R, Malenica B, Silobrčić V. Klinička detekcija celularne imunosti na melanomske antigene in vitro testom inhibicije širenja monocita. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 36.

7.Rogan J, Mujagić H, Malenica B. Citotoksičnost limfocita bolesnika s melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 49.

8.Mujagić H, Kolarić K, Malenica B, Popović Š, Maričić Ž. BCG-imunostimulacija bolesnika s malignim melanomom. Book of abstracts of the Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 80.

9.Mujagić H, Djordjević J, Lovrinčević A, Starović B. The extent of disease and frequency of localisation of metastases in malignant melanoma patients. Book of Abstracts of the Int Jugosl Radiol Congr, Novi Sad, 1980. p. 39.

10.Mujagić H, Malenica B, Nola P. Immunological Prophyle in malignant melanoma patients. Book of abstracts of the Sixth Int Cong Iugosl Oncol, Ljubljana, 1980. p.43.

11.Hadžiomerović V, Mujagić H, Bušić I. Immunological characteristics of patients with carcinomas of the head and neck. Book of abstracts of the Sec Int Congr ENT Soc, Niš, 1980. p. 21.

12. Hadžiomerović V, Mujagić H. The combination of Doxorubicin and radiotherapy in the treatment of patients with carcinoma of head and neck. Book of abstracts of the Sixth Int Congr Yugosl Oncol, Ljubljana, 1980. p. 44.

13. Krnjajić A, Jevrić A, Petronijević S, Mujagić H, Krnjajić Z. PGE2 levels in pregnant BaLb/c mice with transplanted methylcholanthrene Fibrosarcoma. Book of abstracts of the Ninth Congr Yugosl Pharm Soc, Beograd, 1985: p. 193.

14.Krnjaić N, Jevrić A, Mujagić H, Petronijević S, Krnjaić Z. PGE1 levels in pregnant syngeneic BALB/c mice with transplanted methylcholantrene fibrosarcoma. Book of abstracts of the 13th Congress of UYPS, Skopje, 1985: Abs. 291.

15.Mujagić H. Liječenje bolesnika sa malignim tumorom u uvjetima promijenjene ekološke sredine. Zbornik radova Simpozija o životnoj sredini, Novi Sad, 1990. p. 17.

16.Mujagić Z, Mujagić H. The relationship between smoking habits and serum prolactin levels in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 242.

17.Mujagić Z, Mujagić H. Circulating levels of prolactin in relation to age in breast cancer patients. Proceedings of the First Bosnia and Herzegovina Congress of Occupational Medicine with International Participations, Tuzla, 2003. p. 256.


Prof. Dr. med. Sc., Hamza Mujagic

BIOGRAPHY - BIOGRAFIJA


Powered by ORBUS.ONE